New Ceramic Heads With Titanium Sleeves on Retained Femoral Components: Results of Over 500 Revision Total Hip Arthroplasties
The Journal of Arthroplasty · 2024
DOI: 10.1016/j.arth.2024.01.045 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Arthroplasty, 2024. Verfasst von Heather J Roberts und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota. Hauptthemen laut MEDLINE: Reoperation, Arthroplasty, Replacement, Hip, Titanium, Hip Prosthesis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: NIAMS NIH HHS, NHLBI NIH HHS, National Institute of Arthritis and Musculoskeletal and Skin Diseases.
Abstract (Originalsprache)
BACKGROUND: Ceramic heads are frequently combined with titanium sleeves in revision total hip arthroplasties (THAs), ostensibly to protect the ceramic head from existing damage to the retained trunnion. Although widely adopted, data on the performance and safety of this construct are minimal. The purpose of this study was to describe implant survivorships, radiographic results, and clinical outcomes of patients who underwent revision THA with a ceramic head and titanium sleeve on a retained femoral component. METHODS: We identified 516 revision THAs with femoral component retention (328 acetabular-only revisions and 188 bearing surface exchanges) treated with a new ceramic head and titanium sleeve between 2000 and 2020. Mean age at revision was 64 years, 56% were women, and mean body mass index was 30. The indications for revision THA were adverse local tissue reaction (25%), acetabular loosening (24%), dislocation (17%), infection (5%), and other (29%). Kaplan-Meier survivorships were analyzed, radiographs reviewed, and Harris Hip Scores evaluated. Mean follow-up was 4 years (range, 2 to 10). RESULTS: There were no reoperations or failures for ceramic head fracture, taper corrosion, or head/sleeve disengagement. The 10-year survivorship free of any re-revision was 85%. Indications for the 57 re-revisions included dislocation (33), infection (13), acetabular component loosening (7), periprosthetic fracture (2), psoas impingement (1), and sciatic nerve irritation (1). The 10-year survivorship free of any reoperation was 82%. There were an additional 14 reoperations. Radiographically, 1.9% had progressive femoral radiolucent lines, and 4.7% had progressive acetabular radiolucent lines. Mean Harris Hip Score was 81 at 2 years. CONCLUSIONS: New ceramic heads with titanium sleeves in revision THAs with retained femoral components were durable and reliable with no cases of ceramic head fracture or taper complications at mean 4-year follow-up, including those revised for adverse local tissue reaction. LEVEL OF EVIDENCE: IV.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota.
Förderung
- NIAMS NIH HHS
- NHLBI NIH HHS
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- National Institutes of Health
Zitieren
APA
Roberts, H. J., Hannon, C. P., Dilger, O. B., Bedard, N. A., Berry, D. J., & Abdel, M. P. (2024). New Ceramic Heads With Titanium Sleeves on Retained Femoral Components: Results of Over 500 Revision Total Hip Arthroplasties. The Journal of Arthroplasty. https://doi.org/10.1016/j.arth.2024.01.045
Vancouver
Roberts HJ, Hannon CP, Dilger OB, Bedard NA, Berry DJ, Abdel MP. New Ceramic Heads With Titanium Sleeves on Retained Femoral Components: Results of Over 500 Revision Total Hip Arthroplasties. The Journal of Arthroplasty. 2024. doi:10.1016/j.arth.2024.01.045
BibTeX
@article{Roberts2024,
author = {Roberts, Heather J and Hannon, Charles P and Dilger, Oliver B and Bedard, Nicholas A and Berry, Daniel J and Abdel, Matthew P},
title = {New Ceramic Heads With Titanium Sleeves on Retained Femoral Components: Results of Over 500 Revision Total Hip Arthroplasties},
journal = {The Journal of Arthroplasty},
year = {2024},
doi = {10.1016/j.arth.2024.01.045}
}
EUVIMED